

URETHRA STAGING FORM

| CLINICAL <i>Extent of disease before any treatment</i> | STAGE CATEGORY DEFINITIONS | PATHOLOGIC <i>Extent of disease through completion of definitive surgery</i> |
|---|--|---|
| <input type="checkbox"/> y clinical – staging completed after neoadjuvant therapy but before subsequent surgery | TUMOR SIZE: _____ LATERALITY: <input type="checkbox"/> left <input type="checkbox"/> right <input type="checkbox"/> bilateral | <input type="checkbox"/> y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery |
| <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Ta <input type="checkbox"/> Tis <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4 <input type="checkbox"/> Tis pu <input type="checkbox"/> Tis pd <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4 | PRIMARY TUMOR (T) <i>Primary Tumor (T) (male and female)</i> Primary tumor cannot be assessed No evidence of primary tumor Non-invasive papillary, polypoid, or verrucous carcinoma Carcinoma <i>in situ</i> Tumor invades subepithelial connective tissue Tumor invades any of the following: corpus spongiosum, prostate, periurethral muscle Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, anterior vagina, bladder neck Tumor invades other adjacent organs <i>Urothelial (Transitional Cell) Carcinoma of the Prostate</i> Carcinoma <i>in situ</i> , involvement of the prostatic urethra Carcinoma <i>in situ</i> , involvement of the prostatic ducts Tumor invades urethral subepithelial connective tissue Tumor invades any of the following: prostatic stroma, corpus spongiosum, periurethral muscle Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, bladder neck (extraprostatic extension) Tumor invades other adjacent organs (invasion of the bladder) | <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Ta <input type="checkbox"/> Tis <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4 <input type="checkbox"/> Tis pu <input type="checkbox"/> Tis pd <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4 |
| <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1 <input type="checkbox"/> N2 | REGIONAL LYMPH NODES (N) Regional lymph nodes cannot be assessed No regional lymph node metastasis Metastasis in a single lymph node 2 cm or less in greatest dimension Metastasis in a single node more than 2 cm in greatest dimension, or in multiple nodes | <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1 <input type="checkbox"/> N2 |
| <input type="checkbox"/> M0 <input type="checkbox"/> M1 | DISTANT METASTASIS (M) No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis | <input type="checkbox"/> M1 |

| | |
|-----------------------|--------------------------|
| HOSPITAL NAME/ADDRESS | PATIENT NAME/INFORMATION |
|-----------------------|--------------------------|

(continued on next page)

URETHRA STAGING FORM

ANATOMIC STAGE • PROGNOSTIC GROUPS

| CLINICAL | | | | PATHOLOGIC | | | |
|--|--------|-------|----|--|--------|-------|----|
| GROUP | T | N | M | GROUP | T | N | M |
| <input type="checkbox"/> 0a | Ta | N0 | M0 | <input type="checkbox"/> 0a | Ta | N0 | M0 |
| <input type="checkbox"/> 0is | Tis | N0 | M0 | <input type="checkbox"/> 0is | Tis | N0 | M0 |
| | Tis pu | N0 | M0 | | Tis pu | N0 | M0 |
| | Tis pd | N0 | M0 | | Tis pd | N0 | M0 |
| <input type="checkbox"/> I | T1 | N0 | M0 | <input type="checkbox"/> I | T1 | N0 | M0 |
| <input type="checkbox"/> II | T2 | N0 | M0 | <input type="checkbox"/> II | T2 | N0 | M0 |
| <input type="checkbox"/> III | T1 | N1 | M0 | <input type="checkbox"/> III | T1 | N1 | M0 |
| | T2 | N1 | M0 | | T2 | N1 | M0 |
| | T3 | N0 | M0 | | T3 | N0 | M0 |
| | T3 | N1 | M0 | | T3 | N1 | M0 |
| <input type="checkbox"/> IV | T4 | N0 | M0 | <input type="checkbox"/> IV | T4 | N0 | M0 |
| | T4 | N1 | M0 | | T4 | N1 | M0 |
| | Any T | N2 | M0 | | Any T | N2 | M0 |
| | Any T | Any N | M1 | | Any T | Any N | M1 |
| <input type="checkbox"/> Stage unknown | | | | <input type="checkbox"/> Stage unknown | | | |

PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)

REQUIRED FOR STAGING: None

CLINICALLY SIGNIFICANT:

World Health Organization/International Society of Urologic Pathology (WHO/ISUP) grade _____

General Notes:

For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

Histologic Grade (G) (also known as overall grade)

Grading system

- 2 grade system
- 3 grade system
- 4 grade system
- No 2, 3, or 4 grade system is available

Grade

- Grade I or 1
- Grade II or 2
- Grade III or 3
- Grade IV or 4

ADDITIONAL DESCRIPTORS

Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- Lymph-Vascular Invasion Not Present (absent)/Not Identified
- Lymph-Vascular Invasion Present/Identified
- Not Applicable
- Unknown/Indeterminate

m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.

r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.

| | |
|-----------------------|--------------------------|
| HOSPITAL NAME/ADDRESS | PATIENT NAME/INFORMATION |
| | |

(continued from previous page)

URETHRA STAGING FORM

Residual Tumor (R)

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

General Notes (continued):
a prefix designates the stage determined at autopsy: aTNM.

surgical margins is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

neoadjuvant treatment is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

Clinical stage was used in treatment planning (describe): _____

National guidelines were used in treatment planning NCCN Other (describe): _____

 Physician signature

 Date/Time

| | |
|--------------------------------------|---|
| HOSPITAL NAME/ADDRESS | PATIENT NAME/INFORMATION |
|--------------------------------------|---|